Zwitterionic Medical Copolymer Backbone Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel copolymers with enhanced biocompatibility, anti-thrombogenicity, and tailored hydrophobic/hydrophilic characteristics for use in medical products, including implantable and insertable devices, as existing copolymers may not adequately address these requirements.
Innovation Solution
Development of medical copolymers with a polymer backbone comprising C=C groups, radical-substituted C2-C10 cyclic or heterocyclic groups, hydrocarbon-based pendant groups, and zwitterionic pendant groups containing a positively charged quaternary ammonium group and a negatively charged phosphate group, which can be formed through ring-opening metathesis polymerization, mimicking the structure of dipalmitoylphosphatidyl choline to provide enhanced biocompatibility and controlled drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing copolymers are used in medical devices, then basic functionality is provided, but biocompatibility and anti-thrombogenicity are not sufficiently enhanced
Solution Approach 1:
The copolymer incorporates zwitterionic pendant groups at specific locations along the polymer backbone, creating local regions of enhanced biocompatibility and anti-thrombogenicity while maintaining overall structural integrity. The zwitterionic groups are positioned to specifically interact with biological interfaces, providing localized functional enhancement without requiring complete structural redesign of the entire polymer system.
Solution Approach 2:
The invention creates a composite polymer structure combining hydrocarbon-based pendant groups (提供疏水性) with zwitterionic pendant groups (提供亲水性和生物相容性) along the same polymer backbone. This composite approach at the molecular level allows the material to simultaneously exhibit both hydrophobic and hydrophilic characteristics, enabling tailored performance for medical applications while enhancing biocompatibility.
2Reliability
If copolymers with enhanced biocompatibility are developed, then anti-thrombogenicity is improved, but manufacturing complexity increases
Solution Approach 1:
The invention modifies the chemical parameters of the polymer by introducing zwitterionic pendant groups with specific functional characteristics (positive quaternary ammonium and negative phosphate groups). This parameter change at the molecular level directly enhances anti-thrombogenicity by altering the polymer's interaction with blood components, achieving improved reliability through controlled chemical composition rather than complex structural design.
3Object-affected harmful factors
If zwitterionic pendant groups are incorporated into the polymer backbone, then resistance to non-specific protein adsorption is enhanced, but synthesis difficulty increases
Solution Approach 1:
The copolymer is designed as a segmented structure with distinct hydrocarbon-based pendant groups and zwitterionic pendant groups distributed along the polymer backbone. This segmentation allows each functional group to perform its specific role independently - the hydrocarbon groups provide structural framework while the zwitterionic groups specifically resist protein adsorption. The segmented design simplifies synthesis by allowing modular assembly of different monomer units rather than requiring complex one-step polymerization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting copolymers exhibit improved biocompatibility, resistance to non-specific protein adsorption, and tailored hydrophobic/hydrophilic balance, influencing wettability and therapeutic agent diffusivity, thereby enhancing the performance of medical devices and drug delivery systems.
Implementation Method 1
which can be formed through ring-opening metathesis polymerization
Implementation Method 2
a plurality of zwitterionic pendant groups along the polymer backbone that comprise a positively charged quaternary ammonium group (i.e., R4N+, where R4 is an organic radical) and a negatively charged phosphate group
Data Source
AI summary
Medical copolymers are provided which comprise (a) a polymer backbone comprising (i) a plurality of —C═C— groups within the polymer backbone, (ii) a plurality of —R9— groups within the polymer backbone, wherein R9 comprises a radical-substituted C2-C10 cyclic or heterocyclic group, or (iii) both a plurality of —C═C— groups and a plurality of —R9— groups within the polymer backbone, (b) a plurality of hydrocarbon-based pendant groups along the polymer backbone that comprise a saturated or unsaturated carbon chain of at least four carbons in length, and (c) a plurality of zwitterionic pendant groups along the polymer backbone that comprise a positively charged quaternary ammonium group and a negatively charged phosphate group. Methods of forming such copolymers, medical products that contain such copolymers, and methods of making such medical products are also disclosed.